Dexamethasone for COVID-19

• Status: Recruiting
• Trial end date: 2021-09-21
• Target enrollment: 0
• Participant gender: All

Summary

This open label clinical trial is to evaluate two different doses of dexamethasone on the health outcome using World Health Organization ordinal scale at day 28 in hospitalized patients with COVID-19.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Dexamethasone

Criteria

Inclusion Criteria:

• Age ≥ 18 years old

• RT-PCR confirmed COVID-19 infection

• Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula (HFNC) or need supplemental oxygen with oxygen mask or nasal cannula

Exclusion Criteria:

• Underlying disease requiring chronic corticosteroids

• Severe adverse events before admission, i.e. cardiac arrest;

• Contraindication for corticosteroids;

• Death is deemed to be imminent and inevitable during the next 24 hours

• Recruited in other clinical intervention trial

• Pregnancy

• Patient on judicial protection